## Lauren K Truby

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3292852/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Clinical outcome of mechanical circulatory support for refractory cardiogenic shock in the current era. Journal of Heart and Lung Transplantation, 2013, 32, 106-111.	0.6	182
2	Advanced HeartÂFailure. JACC: Heart Failure, 2020, 8, 523-536.	4.1	154
3	Incidence and Implications of Left Ventricular Distention During Venoarterial Extracorporeal Membrane Oxygenation Support. ASAIO Journal, 2017, 63, 257-265.	1.6	152
4	Aortic Insufficiency During Contemporary Left Ventricular Assist Device Support. JACC: Heart Failure, 2018, 6, 951-960.	4.1	106
5	Bridge-to-Decision Therapy With a Continuous-Flow External Ventricular Assist Device in Refractory Cardiogenic Shock of Various Causes. Circulation: Heart Failure, 2014, 7, 799-806.	3.9	96
6	Prognostic Impact of Pulmonary Artery Pulsatility Index (PAPi) in Patients With Advanced Heart Failure: Insights From the ESCAPE Trial. Journal of Cardiac Failure, 2018, 24, 453-459.	1.7	82
7	Feasibility of smaller arterial cannulas in venoarterial extracorporeal membrane oxygenation. Journal of Thoracic and Cardiovascular Surgery, 2015, 149, 1428-1433.	0.8	76
8	Contemporary Outcomes of Venoarterial Extracorporeal Membrane Oxygenation for Refractory Cardiogenic Shock at a Large Tertiary Care Center. ASAIO Journal, 2015, 61, 403-409.	1.6	71
9	Sex-Related Differences in Use and Outcomes of Left Ventricular Assist Devices as Bridge to Transplantation. JACC: Heart Failure, 2019, 7, 250-257.	4.1	66
10	EC-VAD: Combined Use of Extracorporeal Membrane Oxygenation and Percutaneous Microaxial Pump Left Ventricular Assist Device. ASAIO Journal, 2019, 65, 219-226.	1.6	50
11	Risk of severe primary graft dysfunction in patients bridged to heart transplantation with continuous-flow left ventricular assist devices. Journal of Heart and Lung Transplantation, 2018, 37, 1433-1442.	0.6	49
12	Impact of Bridge to Transplantation With Continuous-Flow Left Ventricular Assist Devices on Posttransplantation Mortality. Circulation, 2019, 140, 459-469.	1.6	49
13	Ventricular Assist Device Utilization in Heart Transplant Candidates. Circulation: Heart Failure, 2018, 11, e004586.	3.9	44
14	Dose-dependent association between amiodarone and severe primary graft dysfunction in orthotopic heart transplantation. Journal of Heart and Lung Transplantation, 2017, 36, 1226-1233.	0.6	42
15	Psychosocial Risk and Its Association With Outcomes in Continuous-Flow Left Ventricular Assist Device Patients. Circulation: Heart Failure, 2020, 13, e006910.	3.9	33
16	Incidence and Impact of On-Cardiopulmonary Bypass Vasoplegia During Heart Transplantation. ASAIO Journal, 2018, 64, 43-51.	1.6	32
17	ECMO as a Bridge to Left Ventricular Assist Device or Heart Transplantation. JACC: Heart Failure, 2021, 9, 281-289.	4.1	32
18	Sex Differences in Quality of Life and Clinical Outcomes in Patients With Advanced Heart Failure. Circulation: Heart Failure, 2020, 13, e006134.	3.9	29

LAUREN K TRUBY

#	Article	IF	CITATIONS
19	Incidence and impact of primary graft dysfunction in adult heart transplant recipients: A systematic review and meta-analysis. Journal of Heart and Lung Transplantation, 2021, 40, 642-651.	0.6	25
20	Impact of Obesity on Ventricular Assist Device Outcomes. Journal of Cardiac Failure, 2020, 26, 287-297.	1.7	23
21	Potential for donation after circulatory death heart transplantation in the United States: Retrospective analysis of a limited UNOS dataset. American Journal of Transplantation, 2020, 20, 525-529.	4.7	23
22	Durability and clinical impact of tricuspid valve procedures in patients receiving a continuous-flow left ventricular assist device. Journal of Thoracic and Cardiovascular Surgery, 2016, 151, 520-527.e1.	0.8	22
23	Mechanical Circulatory Support Device Utilization and Heart Transplant Waitlist Outcomes in Patients With Restrictive and Hypertrophic Cardiomyopathy. Circulation: Heart Failure, 2018, 11, e004665.	3.9	22
24	Important role of mechanical circulatory support in acute myocardial infarction complicated by cardiogenic shock. European Journal of Cardio-thoracic Surgery, 2015, 48, 322-328.	1.4	18
25	Donation After Circulatory Death in Heart Transplantation: History, Outcomes, Clinical Challenges, and Opportunities to Expand the Donor Pool. Journal of Cardiac Failure, 2022, 28, 1456-1463.	1.7	18
26	Identification of Undetected Monogenic Cardiovascular Disorders. Journal of the American College of Cardiology, 2020, 76, 797-808.	2.8	17
27	Management of primary graft failure after heart transplantation: Preoperative risks, perioperative events, and postoperative decisions. Clinical Transplantation, 2019, 33, e13557.	1.6	13
28	Proteomic profiling identifies CLEC4C expression as a novel biomarker of primary graft dysfunction after heart transplantation. Journal of Heart and Lung Transplantation, 2021, 40, 1589-1598.	0.6	12
29	Increased Opportunities for Transplantation for Women in the New Heart Allocation System. Journal of Cardiac Failure, 2022, 28, 1149-1157.	1.7	12
30	Angiopoietin-2: marker or mediator of angiogenesis in continuous-flow left ventricular assist device patients?. Journal of Thoracic Disease, 2016, 8, 3042-3045.	1.4	11
31	Impact of heart failure drug therapy on rates of gastrointestinal bleeding in LVAD recipients: An INTERMACS analysis. International Journal of Artificial Organs, 2021, 44, 965-971.	1.4	8
32	Circulating long chain acylcarnitines and outcomes in diabetic heart failure: an HF-ACTION clinical trial substudy. Cardiovascular Diabetology, 2021, 20, 161.	6.8	8
33	Impact of Induction Immunosuppression on Post-Transplant Outcomes of Patients Bridged with Contemporary Left Ventricular Assist Devices. ASAIO Journal, 2020, 66, 261-267.	1.6	6
34	Critically appraising the 2018 United Network for Organ Sharing donor allocation policy. Current Opinion in Anaesthesiology, 2021, Publish Ahead of Print, .	2.0	5
35	Combined Therapy of Ventricular Assist Device and Membrane Oxygenator for Profound Acute Cardiopulmonary Failure. ASAIO Journal, 2017, 63, 713-719.	1.6	4
36	Red Cell Distribution Width Predicts 90 Day Mortality in Continuous-Flow Left Ventricular Assist Device Patients. ASAIO Journal, 2019, 65, 233-240.	1.6	4

LAUREN K TRUBY

#	Article	IF	CITATIONS
37	C-Reactive Protein Levels Predict Outcomes in Continuous-Flow Left Ventricular Assist Device Patients. ASAIO Journal, 2021, Publish Ahead of Print, 884-890.	1.6	4
38	Advanced heart failure patients supported with ambulatory inotropic therapy: What defines success of therapy?. American Heart Journal, 2021, 239, 11-18.	2.7	2
39	Sex-Differences in Cause of Death for Patients Hospitalized for Heart Failure With Reduced Versus Preserved Ejection Fraction (from the ASCEND-HF Trial). American Journal of Cardiology, 2021, 154, 123-126.	1.6	1
40	Reply to Spiliopouloset al European Journal of Cardio-thoracic Surgery, 2016, 49, 1299-1299.	1.4	0
41	Response by Truby and Topkara to Letter Regarding Article, "Impact of Bridge to Transplantation With Continuous-Flow Left Ventricular Assist Devices on Posttransplantation Mortality: A Propensity-Matched Analysis of the United Network of Organ Sharing Database― Circulation, 2019, 140. e942-e943.	1.6	0